A Look at Regeneron Pharmaceuticals’ Product Pipeline

Regeneron Pharmaceuticals (REGN) currently has 15 products in clinical development. It has used its Velocimmune technology to generate all these candidates.

Products currently under development in Phase 1 trials include REGN2810, which targets solid tumors and advanced hematologic malignancies; REGN3767, which targets advanced malignancies; REGN1979, which targets B-cell malignancies as a monotherapy and in combination with cemiplimab; and REGN 3470, which targets the Ebola virus infection.

Other products currently in Phase 1 trials are REGN3500 as a monotherapy and in combination with dupilumab for the treatment of asthma, and REGN1033 for the treatment of muscle wasting diseases.

Regeneron Pharmaceuticals’ products currently in Phase 2 trials include dupilumab for the treatment of EOE (eosinophilic esophagitis), sarilumab for the treatment of polyarticlular course juvenile idiopathic arthritis, cemiplimab for the treatment of metastatic CSCC (cutaneous squamous cell carcinoma), and evinacumab for the treatment of refractory hypercholesterolemia.

Regeneron Pharmaceuticals’ products in Phase 3 trials include Eylea for the treatment of NPDR (non-proliferative diabetic retinopathy) in patients without DME (diabetic macular edema); dupilumab for the treatment of atopic dermatitis, asthma, and nasal polyps; Praluent for LDL (low-density lipoprotein) cholesterol reduction; cemiplimab for the treatment of NSCLC (non-small cell lung cancer) and cervical cancer; and fasinumab for the treatment of osteoarthritis of the knee and hip and chronic low back pain in patients with concomitant osteoarthritis.

The FDA (U.S. Food & Drug Administration) granted breakthrough therapy designation for dupilumab in 2016 for the treatment of atopic dermatitis in patients who are intolerant to topical medication.

Regeneron Pharmaceuticals is expected to incur R&D (research and development) expenses of $6.3 billion for fiscal 2018. Its peers Alimera Sciences (ALIM), Momenta Pharmaceuticals (MNTA), and Pfizer (PFE) are expected to incur R&D expenses of $10.3 million, $148 million, and $7.7 billion, respectively.

In the next part of this series, we’ll take a look at the financial performance of Regeneron Pharmaceuticals.